StockData
Mineralys Therapeutics, Inc. logo

Mineralys Therapeutics, Inc. (MLYS) stock

MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$14.48−0.05 (-0.34%)

Close on Nov 17, 2026Market cap $1.28BP/E –Yield –

Mineralys Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Mineralys Therapeutics's price to book ratio was 2.6× on Nov 11, 2026, against 5.9× a year earlier. Over the last 4 years it ranged from 1.0× to 8.6×, with a median of 2.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.6×−2.4
2025Dec 31, 20255.0×+2.4
2024Dec 31, 20242.6×+1.2
2023Dec 29, 20231.3×–

More Mineralys Therapeutics figures

See a number that looks wrong?